Osimertinib Real World Toxicity Substantially Less than 1st Gen TKIs
Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center discusses Osimertinib and the real world toxicity issues including that it's substantially less than 1st generationg TKIs from the 22nd...
Author: thoraciconcology
Added: 12/29/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 29, 2017 Category: Cancer & Oncology Source Type: podcasts
Acute oncology: new immunotherapy guidelines
Immunotherapies can come with a range of toxicities that require the appropriate management by acute oncology services. In this interview, Liz Gifford of the University Hospital Southampton NHS Founda...
Author: VJOncology
Added: 12/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 13, 2017 Category: Cancer & Oncology Source Type: podcasts
The rarer toxicities of immunotherapy
Immunotherapies can induce a range of common, as well as rare, side effects. These may be difficult for healthcare professionals to spot if they have not observed them previously. In this interview, L...
Author: VJOncology
Added: 12/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 13, 2017 Category: Cancer & Oncology Source Type: podcasts
The systemic anti-cancer dataset (SACT): optimizing immunotherapy toxicity management
Collating data and communicating center experiences is essential to ensure that the best standard of care is provided to patients across geographical boundaries. In this interview, Liz Gifford of the ...
Author: VJOncology
Added: 12/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 13, 2017 Category: Cancer & Oncology Source Type: podcasts
Efficacy of first generation FLT3 inhibitors for AML
New molecules targeting specific gene mutations are showing great potential for precisely treating diseases and lowering the toxicity of treatment. In this interview, recorded at the International Con...
Author: VJHemOnc
Added: 12/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 7, 2017 Category: Cancer & Oncology Source Type: podcasts
The development of novel treatment modalities: regulations and expectations
Novel technologies have the potential to allow us to treat more ailments, but often come at the price of new toxicities. Speaking from the International Conference of Acute Myeloid Leukaemia 2017, Est...
Author: VJHemOnc
Added: 12/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 5, 2017 Category: Cancer & Oncology Source Type: podcasts
When to use bispecifics for AML
As alternatives to chemotherapy are created, the prospect of having treatments with a lower toxicity becomes more tangible. In this video, Prof. John DiPersio, MD, PhD from Washington University Schoo...
Author: VJHemOnc
Added: 11/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Bispecific agents: the future of AML and MDS treatment?
It is crucial that drug toxicity is kept as low as possible to improve the quality of life of patients. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by...
Author: VJHemOnc
Added: 11/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 23, 2017 Category: Cancer & Oncology Source Type: podcasts
BTK inhibitors: toxicity, resistance, and combinations
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses recent developments in BTK inhibitors at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. BTK...
Author: VJHemOnc
Added: 11/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 21, 2017 Category: Cancer & Oncology Source Type: podcasts
Overcoming toxicities when combining PI3K inhibitors with other treatments
Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor to be used in lymphoma, which had remarkable responses on B-cell lymphomas as a single-agent. Nathan Fowler, MD at the University of...
Author: VJHemOnc
Added: 11/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 17, 2017 Category: Cancer & Oncology Source Type: podcasts
Understanding the balance between efficacy and toxicity
John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses the balance between efficacy and toxicity of treatments at the International Workshop on Non-Hodgkin Lym...
Author: VJHemOnc
Added: 11/16/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 16, 2017 Category: Cancer & Oncology Source Type: podcasts
A Supplement That May Block The Toxic Effects of Alcohol
Dr Lundberg shares a possible aid for metabolizing alcohol. (Source: Medscape Internal Medicine Podcast)
Source: Medscape Internal Medicine Podcast - September 26, 2017 Category: Internal Medicine Authors: Medscape Source Type: podcasts
Cisplatin with Radiation, Toxicity Problems with the Standard Regimen
Direct from ASCO 2017<br />Highlights and New Approaches in Head and Neck Cancer<br /><a target='_blank' href='http://cancerGRACE.org/'>http://cancerGRACE.org/...</a>
Author: cancergrace
Added: 08/03/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2017 Category: Cancer & Oncology Source Type: podcasts
What to Do When a Child Has a Toxic Exposure
A free resource helps clinicians identify and manage toxic exposures in children and improve health outcomes. (Source: Medscape Medscape Podcast)
Source: Medscape Medscape Podcast - July 17, 2017 Category: General Medicine Authors: Medscape Source Type: podcasts
